Tirzepatide Half-Life and Pharmacokinetics

Pharmacokinetic parameters in summary

Population mean values from the FDA prescribing information and EMA EPAR. Individual variability is non-trivial; refer to the underlying regulatory documents for inter-individual ranges and special-population data.^[2],[3]

Why five days?

Native GLP-1 has a half-life of approximately 1.5–2 minutes in circulation. Native GIP is similar. Tirzepatide's roughly 5-day half-life is an engineered property, achieved by three combined strategies:

1. N-terminal protection from DPP-4. An α-aminoisobutyric acid (Aib) substitution at position 2 sterically blocks DPP-4 cleavage of the first two N-terminal residues. This single change extends the in-vivo serum stability by orders of magnitude.
2. Albumin binding via fatty diacid. A C20 fatty diacid is attached to the peptide backbone through a γ-glutamate / 2× AEEA spacer. The hydrophobic chain non-covalently binds serum albumin, which physically shields the peptide from renal filtration and slows clearance.
3. Slow absorption from the SC depot. The lipidated peptide self-organizes in the subcutaneous tissue and releases over hours-to-days, contributing both to the long apparent half-life and to the comparatively flat plasma concentration profile week-to-week.

Dose titration logic

Steady-state plasma concentrations are reached after approximately four weeks of continuous weekly dosing. Tirzepatide is titrated upward over a period of months to reduce the incidence of gastrointestinal adverse events. The label-recommended schedule starts at 2.5 mg once weekly and increases in 2.5 mg increments every 4 weeks to a maintenance dose of 5, 10, or 15 mg depending on response and tolerability.

Special populations

• Renal impairment: no dose adjustment is required across mild, moderate, severe, or end-stage renal disease in published PK studies. Caution is advised in patients with severe gastrointestinal disease given the GI-active mechanism.
• Hepatic impairment: no dose adjustment is required for mild, moderate, or severe hepatic impairment based on Child-Pugh classification.
• Age, sex, race, body weight: do not require dose adjustment per regulatory PK analyses.
• Drug interactions: tirzepatide does not appreciably inhibit or induce CYP450 enzymes; the principal interaction concern is delayed gastric emptying, which may alter the absorption of orally co-administered drugs.